7 Hills Pharma appoints Michael S. Perry, CEO of AVITA Medical, as its first Chairman of the Board of Managers. The company is advancing small molecule integrin activators, including 7HP349, to enhance immuno-oncology drugs and vaccines for COVID-19, influenza, and cancer treatments.

7 Hills Pharma is developing 7HP349, a novel immune activator to enhance the effectiveness of COVID-19 and influenza vaccines as well as cancer immunotherapies. This proprietary compound activates integrins, improving cell adhesion and immune responses, and aims to address age-related immune deficiencies, ultimately improving treatment outcomes for vulnerable populations.

7 Hills Pharma appoints Dr. Lionel D. Lewis as Chief Medical Officer, bringing extensive immuno-oncology expertise to advance 7HP349 integrin activator for solid tumor treatment. Learn more about this leadership addition.

7 Hills Pharma forms a Scientific Advisory Board with top immuno-oncology experts to advance its integrin activator program, aiming to enhance checkpoint inhibitors and improve cancer immunotherapy effectiveness.